To be manufactures at its oral dosage facility in Bangalore
Strides Arcolab announced that the Company has received approval from the United States Food & Drug Administration (USFDA) for for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg.According to IMS data as on September 2013, the US market for generic for Tacrolimus is approximately USD 676 million.
The product will be manufactured at the Company's oral dosage facility at Bangalore and marketed directly by Strides in the US market.
Powered by Capital Market - Live News
